[1] WEN Yingjuan CHEN Mo ZHAO Huan CHEN Lijuan WANG Jiang,.Study on Correlation Between “Spleen Governing Muscle” and “Mitochondrial Quality Control” [J]. Modern Traditional Chinese Medicine, 2022, 1(03): 1-8. [doi: 10.13424/j.cnki.mtcm.2022.03.001]
Study on Correlation Between “Spleen Governing Muscle” and “Mitochondrial Quality Control”
- Article number:
- 1672-0571(2022)03-0001-08
- ZTFLH:
- R228
- Code:
- A
- Abstract:
- Abstract：Based on the research of “spleen-muscle-mitochondria”，from the pathology of myasthenia gravis （MG），taking mitochondrial dysfunction as the key point，based on “spleen governing muscle”，combined with the pathogenesis characteristics of “flaccidity syndrome” in traditional Chinese medicine，which is based on spleen deficiency and mixed with deficiency and excess，extend the research on “spleen-muscle-mitochondria quality control”，and the mitochondrial quality control originates from skeletal muscle stem cells and is subject to the dynamic regulation of mitochondria，Therefore，Pueraria lobata and its compatibility may regulate the quality of mitochondria and treat myasthenia gravis through two levels:First，at the level of forming more high-quality mitochondria，starting from skeletal muscle stem cells，through the dynamic regulation of Myod and Pax7 and the activation of P38 MAPK and AMPK signal pathway，protect the proliferation of normal MSCs，ensure the regeneration and repair of skeletal muscle and make high-quality mitochondria active；Second，at the level of dynamic regulation of mitochondria，it mainly focuses on mitochondrial biosynthesis，fusion and division，autophagy and intracellular calcium regulation，forming a highly dynamic plasticity network of mitochondrial vitality to ensure that high-quality mitochondria are full of vitality.
References:
［1］常婷.中国重症肌无力诊断和治疗指南(2020版)[J].中国神经免疫学和神经病学杂志,2021,28(1):1-12.
[2]Li T,Zhang GQ,Li Y,et al.Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis:a meta-analysis[J].Journal of Clinical Neuroscience,2021,85:6-12.
[3]Zhang JN,Chen Y,Chen JX,et al.AChRAb and MuSKAb double-seropositive myasthenia gravis:a distinct subtype?[J].Neurological Sciences,2021,42(3):863-869.
[4]Yamashita R,Shimizu M,Baba K,et al.Anti-MuSK positive myasthenia gravis with anti-Lrp4 and anti-titin antibodies[J].Internal Medicine,2021,60(1):137-140.
[5]文颖娟.葛根功效探微与控制在复方中其功效发挥方向的因素研究[D].成都:成都中医药大学,2007.
[6]文颖娟,李志花.葛根芩连汤及其拆方对UC大鼠结肠平滑肌线粒体跨膜电位的影响[J].陕西中医学院学报,2012,35(6):68-73.
[7]文颖娟,邓中甲.中药葛根功效探微[J].中华中医药学刊,2011,29(1):172-174.
[8]文颖娟,苗海东.葛根芩连汤及其拆方对UC大鼠P选择素及结肠黏膜超微结构的影响[J].时珍国医国药,2012,23(3):635-636.
[9]文颖娟,杨俊超,王超.葛根复方对重症肌无力实验大鼠心肌线粒体酶活性的影响[J].现代中医药,2015,35(1):65-67.
[10]樊一波,文颖娟,李蒙,等.以脾胃为中心的葛根相关配伍对糖尿病心肌病大鼠受损心肌线粒体的改善作用[J].陕西中医,2020,41(10):1351-1355.
[11]樊一波.基于“脾气虚弱”探讨葛根及其配伍对DCM大鼠心肌线粒体的影响[D].咸阳:陕西中医药大学，2019.
[12]朱瑞超.葛根及其配伍调控AngII、AQPS抗DCM大鼠心肌纤维化的作用机制[D].咸阳:陕西中医药大学，2020.
[13]周仲瑛,陈四清,周宁.健脾益肾、熄风通络法治疗重症肌无力[J].江苏中医药,2006,38(12):40-41.
[14]蒋旭宏,黄小民,章正祥,等.裘昌林教授治疗重症肌无力的用药规律探究[J].中国中医急症,2016,25(3):428-432.
[15]张燕平.李声岳治疗眼肌型重症肌无力经验[J].中医杂志,2006,47(2):97.
[16]李蒙,文颖娟,杨俊超,等.葛根及其配伍对重症肌无力大鼠骨骼肌线粒体结构的影响[J].湖南中医药大学学报,2020,40(2):144-149.
[17]李静,文颖娟,杨俊超,等.葛根及其配伍对EAMG大鼠骨骼肌病理形态及骨骼肌线粒体ATP酶的影响[J].四川中医,2020,38(1):51-54.
[18]彭高强，文颖娟,陈茉,等.基于“脾主肌肉”探讨葛根复方对实验性重症肌无力大鼠骨骼肌PGC-1α蛋白的影响［J］.四川中医，2022，40（2）：37-40.
[19]文颖娟.基于“脾主肌肉”的葛根及其配伍对重症肌无力大鼠骨骼肌线粒体调控机制研究［J］.陕西中医药大学,2015-12-01.
[20]文颖娟,杨俊超.葛根复方对实验性自身免疫性重症肌无力大鼠血清RNS和AchR-Ab表达影响[J].中成药,2015,37(11):2357-2361.
[21]杨俊超,文颖娟,王超.葛根复方对重症肌无力大鼠IFN-γ和TGF-β1的影响[J].陕西中医,2015,36(9):1266-1267.
[22]杨俊超,姚远友,文颖娟.葛根及其复方对重症肌无力大鼠肌力恢复和IL-4的影响[J].陕西中医学院学报,2014,37(6):85-87.
[23]宋思琦.Notch/CollagenV/CalcR轴在推拿干预EIMD肌肉干细胞微环境的作用研究[D].成都:成都体育学院,2020.
[24]Latroche C,Weiss-Gayet M,Chazaud B.Investigating the vascular niche:three-dimensional co-culture of human skeletal muscle stem cells and endothelial cells[J].Methods in Molecular Biology(Clifton,N J),2019,2002:121-128.
[25]Relaix F,Bencze M,Borok MJ,et al.Perspectives on skeletal muscle stem cells[J].Nature Communications,2021,12(1):692.
[26]张佳怡,王彤,白玉琢,等.电针介入时机对腰多裂肌损伤模型大鼠Foxo1、Myostatin、Myod蛋白表达的影响[J].世界中医药,2019,14(3):598-601,607.
[27]Giordani L,He GJ,Negroni E,et al.High-Dimensional Single-Cell Cartography Reveals Novel Skeletal Muscle-Resident Cell Populations[J].Molecular cell,2019,74(3):609-621.e6.
[28]刘沛洁,胡毓诗,丁海丽,等.长期离心运动联合推拿对大鼠骨骼肌恢复期干细胞PAX7的影响[A].中国体育科学学会.第十一届全国体育科学大会论文摘要汇编[C].中国体育科学学会:中国体育科学学会,2019:3.
[29]陈茂,洪莉,李素廷,等.肌卫星细胞与其微环境作用及其活化增殖相关通路的研究进展[J].武汉大学学报(医学版),2019,40(4):683-688.
[30]卜凡.耐力运动经AMPK介导的自噬维持老年小鼠骨骼肌卫星细胞干细胞属性[D].重庆:重庆医科大学,2019.
[31]向力,陈绍娟,江淼,等.不同浓度乙酰胆碱对骨骼肌干细胞增殖、分化的影响[J].山东医药,2018,58(14):25-29.
[32]王岑依,梁计陵,司誉豪,等.运动通过调控线粒体质量控制改善肌少症的研究进展[J].中国康复理论与实践,2020,26(9):1066-1070.
[33]张庆.运动调节骨骼肌线粒体质量控制的研究进展[J].体育科研,2020,41(4):52-59,74.
[34]Wang SJ,Chen YS,Li XY,et al.Emerging role of transcription factor EB in mitochondrial quality control[J].Biomedicine & Pharmacotherapy,2020,128:110272.
[35]Ryan TA,Phillips EO,Collier CL,et al.Tollip coordinates parkin-dependent trafficking of mitochondrial-derived vesicles[J].The EMBO Journal,2020,39(11):e102539.
[36]马旗联.UBQLN2介导的线粒体质量控制与肌萎缩侧索硬化症发病的关系[D].苏州:苏州大学,2020.
[37]De R,Mazumder S,Bandyopadhyay U.Mediators of mitophagy that regulate mitochondrial quality control play crucial role in diverse pathophysiology[J].Cell Biology and Toxicology,2021,37(3):333-366.
[38]张程程,杨瀚程,林久涵.PGC-1α在神经退行性疾病中对线粒体质量控制的调控作用[J].中风与神经疾病杂志,2020,37(2):180-183.
[39]Yoshioka K,Fujita R,Seko D,et al.Distinct roles of Zmynd17 and PGC1α in mitochondrial quality control and biogenesis in skeletal muscle[J].Frontiers in Cell and Developmental Biology,2019,7:330.
[40]刘诗瑶,张艳,孔繁达.基于“心脑肾轴”理论探究补肾活血方对慢性心衰大鼠心肌线粒体能量代谢及PGC-1α、NRF-1、mtTFA mRNA表达影响[J].辽宁中医药大学学报,2021,23(5):22-26.
[41]Alam C,Hoque MT,Sangha V,et al.Nuclear respiratory factor 1(NRF-1) upregulates the expression and function of reduced folate carrier(RFC) at the blood-brain barrier[J].FASEB Journal:Official Publication of the Federation of American Societies for Experimental Biology,2020,34(8):10516-10530.
[42]Liu T,Woo JAA,Bukhari MZ,et al.CHCHD10-regulated OPA1-mitofilin complex mediates TDP-43-induced mitochondrial phenotypes associated with frontotemporal dementia[J].The FASEB Journal,2020,34(6):8493-8509.
[43]赵彤.有氧运动通过线粒体分裂调节自噬水平在肝细胞肝癌中的作用及机制[D].上海:中国人民解放军海军军医大学,2020.
[44]江鑫,樊庭宇,孙冰,等.改变肌动蛋白聚合状态调控人成纤维细胞成骨分化的线粒体动力学[J].中国临床解剖学杂志,2020,38(3):263-269.
[45]王美婷,王蓓.线粒体动力学异常在OSAHS靶器官损伤中的作用及机制研究进展[J].医学综述,2019,25(20):3963-3968.
[46]Li M,Wang L,Wang YJ,et al.Mitochondrial fusion via OPA1 and MFN1 supports liver tumor cell metabolism and growth[J].Cells,2020,9(1):121.
[47]郑凯,杨梅桂,闫朝君,等.线粒体动力学与细胞凋亡[J].中国细胞生物学学报,2019,41(8):1467-1476.
[48]米慧,林蓓,管敏鑫.线粒体功能缺陷和神经系统疾病[J].生命科学,2012,24(6):549-557.
[49]白翔宇.线粒体融合蛋白2抑制肝细胞癌发生的作用初步研究[D].开封:河南大学,2020.
[50]Nahapetyan H,Moulis M,Grousset E,et al.Mitochondrial quality control is altered in ATG7-deficient vascular smooth muscle cells and linked to unstable atherosclerotic plaque phenotype[J].Atherosclerosis,2020,315:e18.
[51]Jiang XS,Chen XM,Hua W,et al.PINK1/Parkin mediated mitophagy ameliorates palmitic acid-induced apoptosis through reducing mitochondrial ROS production in podocytes[J].Biochemical and Biophysical Research Communications,2020,525(4):954-961.
[52]Yang PC,Jafri MS.Ca2+ signaling in T lymphocytes:the interplay of the endoplasmic Reticulum,mitochondria,membrane potential,and CRAC channels on transcription factor activation[J].Heliyon,2020,6(3):e03526.
[53]Svagua T,Martini cˇ M,Martini c＇ M,et al.Mitochondrial unfolded protein response,mitophagy and other mitochondrial quality control mechanisms in heart disease and aged heart[J].Croatian Medical Journal,2020,61(2):126-138.
[54]李琴.慢性间歇性低压低氧通过FUNDC1调节线粒体质量介导缺血性心肌的保护作用[D].成都:成都医学院,2020.
[55]Kamino H,Nakamura Y,Tsuneki M,et al.Mieap-regulated mitochondrial quality control is frequently inactivated in human colorectal cancer[J].Oncogenesis,2016,4:e181.
[56]辛国松,尚明,王昊,等.红景天苷对大鼠骨骼肌钙调节影响研究[J].哈尔滨商业大学学报(自然科学版),2018,34(3):260-263.
[57]许文华,韩莹莹,汪思应,等.鼠源乙酰胆碱受体α亚基97-116肽段免疫Lewis鼠诱导实验性重症肌无力模型[J].中国神经精神疾病杂志,2006,32(2):179-180.
Memo
基金项目：国家自然科学基金项目（81202642）；陕西省科学技术厅项目（2017SF-323）；第四批全国中医（临床、基础）优秀人才研修项目（国中医药人教发［2017］24号）；2021年度陕西中医药大学校级科研课题（国家基金培育面上项目6）